LONDON – Medivir AB raised €30.8 million (US$41 million) in a private placement that brings in international institutional investors in the lead up to the start of Phase III trials of the lead product, TMC435, a protease inhibitor for treating hepatitis C (HCV) infections. (BioWorld International)

LONDON – At a time when venture capital funding for early stage companies is increasingly hard to come by, Advent Venture Partners has brought some cheer with the final closing at £75 million (US$120 million) of its first dedicated life sciences fund. (BioWorld International)